(TheNewswire)
Calgary, Alberta – TheNewswire - August 17, 2022 - Ocumetics Technology Corp. (“ Ocumetics ” or the“ Company ”) ( TSXV:OTC) (FRA:2QBO) is pleasedto announce that its common shares have commenced trading on theFrankfurt Stock Exchange under the symbol "2QBO". TheCompany's common shares will continue to trade on the TSX VentureExchange under the symbol “OTC”.
The Company has listed on the Frankfurt Stock Exchangeto provide greater trading visibility and convenience forinternational investors, resulting in more liquidity and greaterreach.
"The appeal of our adaptive intraocular lenstechnology to international investors, and numerous requests fromthose investors, motivated us to pursue this listing,” said Dr. MarkLee, CEO of Ocumetics. “We look forward to increasing our base ofinternational investors and sharing development progress of ouraccommodating intraocular lens with this group”, adds Dr. Lee.
About Ocumetics
Ocumetics Technology Corp. ( TSXV: OTC) (FRA: 2QBO) is a Canadianresearch and product development company that specializes in adaptivelens designs. Ocumetics is in the preclinical study stage of agame-changing technology for the ophthalmic industry. Ocumetics hasdeveloped an expandable intraocular lens that fits within the naturallens compartment of the eye potentially to eliminate the need forcorrective lenses. It is designed to allow the eye’s naturalmuscle activity to shift focus from distance to near.
FOR FURTHER INFORMATION, PLEASECONTACT:
Dr. Mark Lee
President and CEO
(604) 832-6052
Neither the TSXVenture Exchange nor its Regulation Services Provider (as that term isdefined in the policies of the TSX Venture Exchange) acceptsresponsibility for the adequacy or accuracy of this release.
Copyright (c) 2022 TheNewswire - All rights reserved.